仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Cabiralizumab （FPA 008） is an anti-CSF1R monoclonal antibody （MAb）. Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis （RA）. Cabiralizumab can combine with Nivolumab （HY-P9903） for lung cancer research
您的位置：
